Naslov
Rheumatoid factor level increased by the toclizumab in rheumatoid arthritis patients with good clinical response and previous inadequate response to TNF inhibitors

Autori
Martinovic Kaliterna, D ; Radic, M ; Perkovic, D ; Marasovic Krstulovic, D ; Marinovic, I ; Boric, K ; Aljinovic, J

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Skup
10th Central European Congress of Rheumatology CECR 2014.

Mjesto i datum
Beč, Austrija, 06.12.2014. - 07.12.2014

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
: rheumatoid factor, tocilizumab, clinical response

Sažetak
The possible underlying mechanisms whereby IL-6 blocking therapy could lead to alterations of RF are not understood. It is known that IL-6 enhances the production of auto antibodies such as RF so these results are completely unexpected. Possible interactions between antibodies and cytokines are numerous. One additional possible explanation for these findings might be that blockade of IL-6 signalling by TCZ directly interferes with B cell diferentiation, germinal centre formation and subsequent autoantibody production. In the long term for RA patients with high RF levels anti TNT-IR B cell-depleting therapy might be a better choice.

Izvorni jezik
Engleski

POVEZANOST RADA